Léim ar aghaidh chuig an bpríomhábhar
Gnáthamharc

Medicinal Products

Dáil Éireann Debate, Wednesday - 11 February 2026

Wednesday, 11 February 2026

Ceisteanna (317)

Ken O'Flynn

Ceist:

317. Deputy Ken O'Flynn asked the Minister for Health to outline the policy or decision framework used by the Health Service Executive when considering prevention-based outcomes, including reductions in the future incidence of type 2 diabetes and cardiovascular disease, in medicines reimbursement decisions under the Health (Pricing and Supply of Medical Goods) Act 2013; and whether the Department has issued, or intends to issue, policy guidance on how long-term prevention savings are weighted in value-for-money assessments. [10656/26]

Amharc ar fhreagra

Freagraí scríofa

Under the Health (Pricing and Supply of Medical Goods) Act 2013, the HSE has statutory responsibility for decisions on the pricing and reimbursement of medicines and medical devices including GLP-1 medications; therefore, the matter has been referred to the HSE for attention and direct reply to the Deputy.

Roinn